Synaptogenix reports disappointing data from Phase II Alzheimer’s trial

Synaptogenix has reported topline findings from the National Institute of Health (NIH)-sponsored Phase II clinical trial of its lead therapeutic candidate, Bryostatin-1, to treat advanced Alzheimer’s disease (AD). According to the findings, the trial failed to meet the primary endpoint with statistical significance.